Literature DB >> 22999694

How dry is "OAB-dry"? Perspectives from patients and physician experts.

Jennifer T Anger1, Thuy X Le, Helen A Nissim, Lisa Rogo-Gupta, Rezoana Rashid, Ajay Behniwal, Ariana L Smith, Mark S Litwin, Larissa V Rodriguez, Alan J Wein, Sally L Maliski.   

Abstract

PURPOSE: Overactive bladder is subtyped into overactive bladder-wet and overactive bladder-dry, based on the presence or absence, respectively, of urgency incontinence. To better understand patient and physician perspectives on symptoms among women with overactive bladder-wet and overactive bladder-dry, we performed patient focus groups and interviews with experts in urinary incontinence.
MATERIALS AND METHODS: Five focus groups totaling 33 patients with overactive bladder symptoms, including 3 groups of overactive bladder-wet and 2 groups of overactive bladder-dry patients, were conducted. Topics addressed patient perceptions of overactive bladder symptoms, treatments and outcomes. A total of 12 expert interviews were then done in which experts were asked to describe their views on overactive bladder-wet and overactive bladder-dry. Focus groups and expert interviews were transcribed verbatim. Qualitative data analysis was performed using grounded theory methodology, as described by Charmaz.
RESULTS: During the focus groups sessions, women screened as overactive bladder-dry shared the knowledge that they would probably leak if no toilet were available. This knowledge was based on a history of leakage episodes in the past. Those few patients with no history of leakage had a clinical picture more consistent with painful bladder syndrome than overactive bladder. Physician expert interviews revealed the belief that many patients labeled as overactive bladder-dry may actually be mild overactive bladder-wet.
CONCLUSIONS: Qualitative data from focus groups and interviews with experts suggest that a spectrum exists between very mild overactive bladder-wet and severe overactive bladder-wet. Scientific investigations are needed to determine whether urgency without fear of leakage constitutes a unique clinical entity.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22999694      PMCID: PMC3571660          DOI: 10.1016/j.juro.2012.07.044

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  A synthesis technique for grounded theory data analysis.

Authors:  Y D Eaves
Journal:  J Adv Nurs       Date:  2001-09       Impact factor: 3.187

Review 2.  Interstitial cystitis and frequency-urgency syndrome (OAB syndrome).

Authors:  Tomohiro Ueda; Grannum R Sant; Philip M Hanno; Naoki Yoshimura
Journal:  Int J Urol       Date:  2003-10       Impact factor: 3.369

3.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Am J Obstet Gynecol       Date:  2002-07       Impact factor: 8.661

4.  Overactive bladder and painful bladder syndrome: there need not be confusion.

Authors:  Paul Abrams; Philip Hanno; Alan Wein
Journal:  Neurourol Urodyn       Date:  2005       Impact factor: 2.696

5.  Factors that distinguish continent from incontinent older adults with detrusor overactivity.

Authors:  Lisa J Rosenberg; Derek J Griffiths; Neil M Resnick
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

6.  Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis.

Authors:  Man-Jung Hung; Esther Shih-Chu Ho; Pao-Sheng Shen; Mou-Jong Sun; Alex Tong-Long Lin; Gin-Den Chen
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

7.  Women's experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups.

Authors:  Jennifer T Anger; Helen A Nissim; Thuy X Le; Ariana L Smith; Una Lee; Catherine Sarkisian; Mark S Litwin; Shlomo Raz; Larissa V Rodriguez; Sally L Maliski
Journal:  Neurourol Urodyn       Date:  2011-04-28       Impact factor: 2.696

8.  The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey.

Authors:  Karin S Coyne; Chris Payne; Samir K Bhattacharyya; Dennis A Revicki; Christine Thompson; Ron Corey; Timothy L Hunt
Journal:  Value Health       Date:  2004 Jul-Aug       Impact factor: 5.725

9.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

10.  Misconceptions and miscommunication among aging women with overactive bladder symptoms.

Authors:  Ariana L Smith; Helen A Nissim; Thuy X Le; Aqsa Khan; Sally L Maliski; Mark S Litwin; Catherine A Sarkisian; Shlomo Raz; Larissa V Rodríguez; Jennifer T Anger
Journal:  Urology       Date:  2010-10-23       Impact factor: 2.633

View more
  3 in total

1.  Important role of physicians in addressing psychological aspects of interstitial cystitis/bladder pain syndrome (IC/BPS): a qualitative analysis.

Authors:  Gregory Kanter; Katherine A Volpe; Gena C Dunivan; Sara B Cichowski; Peter C Jeppson; Rebecca G Rogers; Yuko M Komesu
Journal:  Int Urogynecol J       Date:  2016-08-31       Impact factor: 2.894

2.  Short-term Effects of a Systematized Bladder Training Program for Idiopathic Overactive Bladder: A Prospective Study.

Authors:  Hahn-Ey Lee; Sung Yong Cho; Sangim Lee; Myong Kim; Seung-June Oh
Journal:  Int Neurourol J       Date:  2013-03-31       Impact factor: 2.835

3.  A meta-ethnography to understand the experience of living with urinary incontinence: 'is it just part and parcel of life?'

Authors:  Francine Toye; Karen L Barker
Journal:  BMC Urol       Date:  2020-01-16       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.